Pre‐morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Issue 3 (1st June 2015)

• Record Type: Journal Article
• Authors: Paganoni, Sabrina; Hyman, Theodore; Shui, Amy; Allred, Peggy; Harms, Matthew; Liu, Jingxia; Maragakis, Nicholas; Schoenfeld, David; Yu, Hong; Atassi, Nazem; Cudkowicz, Merit; Miller, Timothy M.
• Is Part Of: Muscle & nerve. Volume 52:Issue 3(2015:Sep.)
• Page Start: 339
• Page End: 343
• Publication Date: 2015-06-01
• Subjects: Neuromuscular diseases -- Periodicals; Muscles -- Periodicals; Nerves -- Periodicals; 616.74
• DOI: 10.1002/mus.24688
• Languages: English
• ISSNs: 0148-639X

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <p> <italic>Introduction:</italic> The aim of this study was to determine whether a history of pre‐morbid type 2 diabetes mellitus (DM2) is a prognostic factor in amyotrophic lateral sclerosis (ALS). <italic>Methods:</italic> The relationship between DM2 and survival was analyzed in a study population consisting of 1, 322 participants from 6 clinical trials. <italic>Results:</italic> Survival did not differ by diabetes status (log‐rank test, <italic>P</italic> = 0.98), but did differ by body mass index (BMI) (log‐rank test, <italic>P</italic> = 0.008). In multivariate analysis, there was no significant association between diabetes and survival (<italic>P</italic> = 0.18), but the risk of reaching a survival endpoint decreased by 4% for each unit increase in baseline BMI (HR 0.96, 95% CI 0.94–0.99, <italic>P</italic> = 0.001). DM2 was less prevalent among ALS clinical trial participants than predicted. <italic>Conclusions:</italic> A history of pre‐morbid DM2 is not an independent prognostic factor in ALS clinical trial databases. The low DM2 prevalence rate should be examined in a large, prospective study to determine whether DM2 affects ALS risk. <italic>Muscle Nerve</italic> 52:339–343, 2015</p> </abstract>